

**Copyright Information of the Article Published Online**

|  |  |
| --- | --- |
| **TITLE** | Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do |
| **AUTHOR(s)** | Yolanda Sanchez-Torrijos, Javier Ampuero, Manuel Romero-Gómez |
| CITATION | Sanchez-Torrijos Y, Ampuero J, Romero-Gómez M. Cardio­vascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. *World J Hepatol* 2017; 9(15): 697-703 |
| URL | http://www.wjgnet.com/1948-5182/full/v9/i15/697.htm |
| DOI | http://dx.doi.org/10.4254/wjh.v9.i15.697 |
| OPEN ACCESS | This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| CORE TIP | Non-alcoholic fatty liver disease is a growing condition due to the current lifestyle. It is considered the liver manifestation of the metabolic syndrome, so it is strongly related to cardiovascular disease. Given that is one of the main indications of liver transplantation, it is essential to carry out an adequate assessment of the pre-transplant cardiovascular risk, as well as an individualized management of the patient in the post-transplantation period (due to the pre-existent cardiovascular risk factors and the immunosuppressive therapy). |
| KEY WORDS | Cardiovascular risk; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Pre-transplant assessment; Liver transplantation |
| COPYRIGHT  | © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| NAME OF JOURNAL | World Journal of Hepatology |
| ISSN | 1948-5182 |
| PUBLISHER | Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA |
| WEBSITE | Http://www.wjgnet.com |

MINIREVIEWS

Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do

Yolanda Sanchez-Torrijos, Javier Ampuero, Manuel Romero-Gómez

Yolanda Sanchez-Torrijos, Javier Ampuero, Manuel Romero-Gómez, Unidad Intercentros de Aparato Digestivo, Hospitales Universitarios Virgen del Rocio - Virgen Macarena, 41013 Sevilla, Spain

Javier Ampuero, Manuel Romero-Gómez, Instituto de Biome­dicina de Sevilla, 41013 Sevilla, Spain

Javier Ampuero, Manuel Romero-Gómez, Centro de In­vestigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 Madrid, Spain

Author contributions:Ampuero J contributed as guarantor of the article; Ampuero J contributed to review design; all authors contributed to drafting the manuscript.

Correspondence to:Javier Ampuero, MD, PhD, Unidad Intercentros de Aparato Digestivo, Hospitales Universitarios Virgen del Rocio - Virgen Macarena, Avenida Manuel Siurot s/n, 41013 Sevilla, Spain. javi.ampuero@gmail.com

Telephone:+34-95-5015761Fax: +34-95-5015899

Received: January 28, 2017 Revised:April 7, 2017 Accepted:April 23, 2017

Published online: May 28, 2017

**Abstract**

Non-alcoholic fatty liver disease (NAFLD) is increasing considerably due to the current lifestyle, which means that it is becoming one of the main indications for liver transplantation. On the other hand, there is a strong association between NAFLD and cardiovascular disease. This has been evidenced in many studies revealing a higher presence of carotid plaques or carotid intima-media thickness, leading to cardiovascular events and, ultimately, mortality. According to the liver transplant guidelines, screening for heart disease in trans­plant candidates should be performed by electrocar­diogram and transthoracic echocardiography while a stress echocardiogram should be reserved for those with more than two cardiovascular risk factors or greater than 50 years old. However, there are no specific recommendations in NAFLD patients requiring a liver transplantation, despite its well-known cardiovascular risk association. Many studies have shown that these patients probably require a more exhaustive assessment and a global approach including other specialists such as cardiologists or nutritionists. Also, the incidence of cardiovascular disease is also increased in NAFLD patients in the post-transplantation period in comparison with other etiologies, because of the pre-existent risk factors together with the immunosuppressive therapy. Therefore, an early intervention on the lifestyle and the individualized selection of the immunosuppressive regimen could lead to a modification of the cardiovascular risk factors in NAFLD patients requiring a liver transplantation.

**Key words:** Cardiovascular risk; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Pre-transplant assessment; Liver transplantation

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

Sanchez-Torrijos Y, Ampuero J, Romero-Gómez M. Cardio­vascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. *World J Hepatol* 2017; 9(15): 697-703 Available from: URL: http://www.wjgnet.com/1948-5182/full/v9/i15/697.htm DOI: http://dx.doi.org/10.4254/wjh.v9.i15.697

**Core tip:** Non-alcoholic fatty liver disease is a growing condition due to the current lifestyle. It is considered the liver manifestation of the metabolic syndrome, so it is strongly related to cardiovascular disease. Given that is one of the main indications of liver transplantation, it is essential to carry out an adequate assessment of the pre-transplant cardiovascular risk, as well as an individualized management of the patient in the post-transplantation period (due to the pre-existent cardiovascular risk factors and the immunosuppressive therapy).

**INTRODUCTION**

Non-alcoholic fatty liver disease (NAFLD) is a clinical-pathological condition that encompasses a wide range of liver damage not caused by chronic alcohol con­sumption, including steatosis, non-alcoholic steatohepatitis (NASH) and cirrhosis[1]. NAFLD is considered a hepatic manifestation of metabolic syndrome. Its prevalence has increased considerably over last years, especially in Western countries, due to the current lifestyle (diet, sedentary lifestyle, obesity)[2,3]. It has been calculated that up to 30% of the population shows NAFLD, representing up to the 70% in patients with type 2 diabetes mellitus (DM)[4]. On the other hand, the prevalence of NASH (characterized by the presence of inflammation) is around 3%-5%. In NASH patients, cardiovascular (CV) risk represents one of the leading causes of mortality due to the frequent association with dyslipidemia, DM and other features of metabolic syndrome[5]. In fact, NASH patients suffer more subclinical atherosclerosis, heart disease, and CV clinical events than those without it[6]. This latter, together with NASH has become the second cause of liver transplantation (LT) in the United States and Europe[7], makes especially relevant the adequate cardiovascular assessment in LT setting.

**CV RISK IN NAFLD PATIENTS**

Several studies have clearly demonstrated the link between NAFLD and CV risk. It is not surprising, con­sidering that they share many risk factors derived from metabolic syndrome (such as obesity, insulin resistance, DM, sedentary lifestyle, hypertension, dyslipidemia) and genetics (PNPLA3, TM6SF2)[8]. Gut microbiota also plays an important role. In both mice and humans, a high-fat diet results in an increase of lipopolysaccharides in plasma (a cellular component of Gram-negative bacteria) by modifying the microbiota and, therefore, the intestinal permeability. That is the reason to increase TLR4 receptor expression, stimulating liver cells to produce inflammatory cytokines and creating a systemic pro-inflammatory status, which favors atherosclerosis[9,10]. According to CV risk, we can classify it in three steps: Subclinical atherosclerosis, clinical events, and mortality.

Firstly, a higher prevalence of subclinical athero­sclerosis has been well-documented (Table 1). In 2005, Brea *et al*[11] published that NAFLD patients showed an increased carotid artery intima-media thickness (CIMT) and a higher prevalence of carotid plaques (50% *vs* 25%) compared to healthy controls. Regarding NAFLD subjects, NASH patients showed greater subclinical atherosclerosis in comparison with those with simple steatosis and the CV risk was progressively increased according to liver fibrosis[11]. Later, Kim *et al*[12] identified that patients with NAFLD had a higher percentage of coronary artery calcification (by computerized tomography) independently of other known factors. More recently, Puchner *et al*[13] again assessed the link between NAFLD and advanced coronary arterial disease. After performing a coronariography by computerized tomography, they found that the presence of significant coronary stenosis (16% *vs* 5%), global carotid plaques (78% *vs* 24%) and high-risk carotid plaques (59% *vs* 19%) were more prevalent in individuals with NAFLD. All of these findings have been confirmed in a recent meta-analysis, as NAFLD patients showed a greater link with subclinical atherosclerosis regarding CIMT [OR 2.04 (95%CI: 1.65-2.51)] and the presence of carotid plaques [OR 2.82 (95%CI: 1.87-4.27)][14]. Secondly, NAFLD patients suffer more CV events than the overall population. In 2016, Fracanzani *et al*[15] aimed to evaluate the incidence of CV and cerebrovascular events in patients with NAFLD, who had been monitored for 10 years. Patients presented a higher number of CV events than the control group (19% *vs* 10%), being the presence of carotid plaques [OR 5.08 (95%CI: 2.56-10.95)] and liver steatosis [OR 1.99 (95CI: 1.01-3.94)] the main risk factors[15]. As a consequence of the higher prevalence of subclinical atherosclerosis and clinical events, CV mortality is ultimately increased as well. In fact, CV-related death appears to be one of the leading causes of death in most of the studies in NASH patients (Table 2). Ekstedt *et al*[16] followed-up 229 patients during more than 30 years, concluding that CV disease was the first cause of mortality for NASH patients without cirrhosis.

Taking all together, the European Association for the Study of the Liver recommend screening for CV disease in patients with NAFLD, irrespective of the presence of other traditional risk factors[17].

**CV EVALUATION PRE-LT**

CV disease is a major cause of death in post-LT knowing that this risk is bigger in patients showing pre-LT risk factors (irrespective of the etiology). For example, coronary artery disease has been observed in as many as 60% of potential LT candidates and, obviously, its presence increases the CV morbi-mortality pre and post-surgery[18]. Therefore, it is essential an adequate CV assessment to prevent these complications and increase post-LT survival rates.

To be included on the liver transplant list, com­prehensive evaluation must be performed to evaluate the peri-surgery risk that could prevent from good long-term results. Regarding to CV assessment, current recommen­dations include[19]: (1) to carry out an electrocardiogram and a trans-thoracic echocardiography to rule out underlying heart disease; (2) in patients with > 2 CV risk factors or those older than 50 years old, an ergometry or a stress echocardiogram with dobutamine to detect subclinical ischemic cardiopathy; and (3) whether a significant coronary artery disease is detected during the usual evaluation, a coronariography must be performed (if this latter results effective, the survival rate after LT is similar to those who do not have previous CV disease[20,21]). Sometimes, non-invasive methods to screen for CV disease have low sensitivity and specificity compared to other tests (*i.e*., angiography)[22]. However, there is no sufficient evidence to recommend invasive tests to evaluate CV risk before LT in asymptomatic patients. Therefore, the American Heart Association and the American College of Cardiology Foundation[23] propose to perform a coronariography in CV high-risk candidates, defined as those who have > 2 CV risk factors (DM, age > 60 years, smokers, AHT, and dyslipidemia). On the other hand, they recommend non-invasive stress tests in those patients with low risk of CV disease[24].

Given that CV risk factors before LT have a great impact, it has been proposed that the Framingham Risk Score (an algorithm to predict CV risk at 10 years including age, sex, smoking, DM, arterial hypertension, and dyslipidemia) could be useful for predicting post-LT CV risk in candidate patients. This strategy could lead to performing individualized diagnostic and therapeutic tests depending on the score[25].

Clinical guidelines for NAFLD patients recommend that CV risk must be carefully evaluated in LT setting because theoretically these subjects have more risk factors to suffer CV-related clinical events and mortality. Even more, some of them probably would require invasive tests but the best method remains unclear. The British guideline[26] proposes the evaluation of the functional capacity of the patient measured by the MET unit (energy expenditure during physical activity), guiding the following tests according to the result. Consequently, patients able to climb at least two flights of stairs (equivalent to 4 METs) and those who do not present CV risk factors, may not require further tests. On the other hand, those with a MET < 4 or showing at least one CV risk factors (myocardial infarction, heart failure, stroke/transient ischaemic attack, renal dysfunction, DM requiring insulin therapy) will need a stress echocardiogram or cardiopulmonary exercise test. Likewise, they recommend the simultaneous evaluation with a cardiologist in CV high-risk patients, especially those who have suffered a CV disease before LT[23]. Despite all this, pre-LT CV assessment in NAFLD patients is not routinely different to those patients who have cirrhosis for other etiologies.

**CV RISK IN NAFLD POST-LT**

Post-LT survival rates have been increasing over time, due to the loss of the liver graft is less common and the short-term mortality is lower[27]. After the transplant, patients usually gain weight, and the incidence of meta­bolic syndrome is greater (as much as two-thirds of patients at 5 years) probably related to the lifestyle and the immunosuppressive treatment, respectively[28,29]. In this scenario, metabolic and CV complications are currently the main responsible for affecting the mid- and long-term survival.

Among non-liver-related 1-year mortality after the LT, CV disease is the second cause after tumors, followed by infections and kidney failure[30]. Madhwal *et al*[31], based on a meta-analysis including twelve observational studies, observed that CV events were present in 13.6% (95%CI: 9%-18%) of NAFLD patients within 10 years. Also, they noted that the incidence of CV disease was especially relevant in those who had additionally metabolic syndrome (four times higher of suffering a CV event)[31]. Precisely, NAFLD patients who required LT are older and have more prevalence of DM and obesity (as well as chronic kidney failure or previous CV disease) in opposition to the rest of etiologies[32].

The prevalence of metabolic syndrome is around 50%-60% of the post-LT population[28,33], influenced by the appearance of several risk factors. Obesity (BMI > 30 kg/m2) is approximately 24%-64% after LT[27], due to the fact that the weight increases after the operation (reversion of cirrhosis and its hypercatabolic state, increase in appetite, absence of the chronic disease, effects of steroids) which means an increase in DM and dyslipidemia, as well as in vascular events and kidney disease[34]. On the other hand, DM (the most important risk factor of NAFLD) is diagnosed in 10%-64% of post-LT patients[28,35], and is being considered more and more the main complication after LT. Its appearance is multifactorial, but the main modifiable factor (apart from lifestyle) is the choice and dose of the immuno­suppressive therapy. Corticoids have diabetogenic effects producing resistance to insulin and increasing the gluconeogenesis, while the calcineurin inhibitors can directly damage the pancreatic cells (tacrolimus has a significantly higher risk than cyclosporine[36]). The immunosuppressive therapy is also responsible, at least in part, of the appearance of post-transplant AHT (40%-85%) and dyslipidemia (40%-66%)[37] (Table 3). All of this means that the liver disease can return after the LT (*de novo* NAFLD). Out of NASH patients who are transplanted, this entity reappears in 75%, being the post-LT hypertriglyceridemia, BMI and steroid treatment, the main risk factors[38] (causing a positive feedback for post-LT CV risk).

In this scenario, several studies have evaluated whether patients with NAFLD show a higher risk of post-LT CV disease in comparison with other etiologies. Yalamanchili *et al*[39] evaluated 2152 patients with liver cirrhosis, of which 12% had NAFLD or cryptogenic cirrhosis. Survival rate at 10 years after the LT was similar regardless of the etiology, but a significant increase was observed in CV mortality in NAFLD patients (21% *vs* 14%)[39]. VanWagner *et al*[40] compared the incidence of CV events between NAFLD and alcohol after the LT. Authors observed an increase in CV-related 1-year mortality after LT in NAFLD group (26% *vs* 8%) and, more interestingly, the most of the CV events occurred in the peri-surgery period (70%)[40]. The same research group has recently determined a group of risk factors clearly associated with post-LT CV mortality: Age > 55 years old, male sex, DM, and kidney failure[32]. Wang *et al*[41] performed a meta-analysis in NAFLD patients to estimate post-LT results regarding overall survival, CV mortality, sepsis and liver graft failure. Authors concluded that survival rates were similar in patients with or without NAFLD, as far as 5 years after LT. However, it was found that NAFLD patients were more likely to die because of CV complications [OR 1.65 (95%CI: 1.01-2.70)][41].

**RECOMMENDATIONS IN NAFLD LIVER TRANSPLANT**

***Pre-liver-transplantation recommendations***

Taking into account the information exposed before, the pre-LT CV assessment in patients with NAFLD should be more exhaustive than in the rest of etiologies. However, there are no specific recommendations probably due to there is no an ideal procedure regarding cost, availability, and reliability.

NAFLD is not considered a CV risk criterion to influence the decision of the selection of the CV evaluation in the pre-LT assessment. Consequently, many NAFLD patients only undergo a trans-thoracic echocardiogram or a computerized coronary tomography with calico-score. Some authors have proposed the stress echo­cardiography with dobutamine as an initial test in NAFLD candidates for LT because it shows a high negative predictive value to detect low-risk patients[42]. In high CV risk patients (age > 55 years, male gender, DM, kidney failure), it probably should be the initial test.

NAFLD is a condition that, more than a specific treatment, needs a multidisciplinary approach whose aim is a dramatic change in the lifestyle[43]. Thus, it is crucial to have a systematic intervention of a nutritionist during the LT evaluation in NAFLD patients (overweight, obesity, unhealthy diet) to reinforce and maintain a healthy lifestyle after the LT[44].

***Post-liver-transplantation recommendations***

Given that liver transplant recipients have an increased risk of CV disease, an early and effective treat­ment is required, as well as changing of the other risk factors (lifestyle, treatment of co-morbidities, immunosuppressive therapy). One example is the obligation of starting the treatment to control AHT, dyslipidemia or DM as soon as possible[44].

Regarding the immunosuppressive drugs, most of them can cause and enhance various CV risk factors. Mycophenolate mofetil is associated with an increased risk of CV disease in post-LT patients[45]. More recently, the use of mTOR inhibitors (sirolimus, everolimus) was associated to lower CV risk than calcineurin inhibitors[46]. Therefore, mTOR inhibitors could be considered for patients with metabolic syndrome and multiple CV risk factors, such as NAFLD patients. Nevertheless, these findings must be confirmed and validated in prospective cohorts. On the other hand, we should use a steroid-free regimen (or an early steroid withdrawal) preferably con­sidering an, for example, a basiliximab-based induction therapy[26].

A healthy diet and regular exercise are effective and complementary therapies[47]. Exercise is effective to lower the CV risk in non-transplant patients, but the connection between the benefits and the possible damage of regular exercise after LT has not been established. Also, there are no data concerning the impact of these exercise programs on the prevalence of metabolic syndrome or its individual components after LT.

**CONCLUSION**

The increased CV risk in patients with NAFLD, compared to other etiologies of liver disease, has important implications both in pre- and post-LT. An adequate stratification of CV risk and an early detection of the different features of metabolic syndrome is required to prevent or decrease CV-related morbi-mortality. In this scenario, an active intervention on lifestyle and an individualized management of immunosuppression could be the most suitable strategies to maintain an adequate balance between risks and benefits.

**REFERENCES**

1 **Masarone M**, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. *Rev Recent Clin Trials* 2014; **9**: 126-133 [PMID: 25514916]

2 **Barrera F**, George J. The role of diet and nutritional intervention for the management of patients with NAFLD. *Clin Liver Dis* 2014; **18**: 91-112 [PMID: 24274867 DOI: 10.1016/j.cld.2013.09.009]

3 **Golabi P**, Otgonsuren M, Cable R, Felix S, Koenig A, Sayiner M, Younossi ZM. Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). *Health Qual Life Outcomes* 2016; **14**: 18 [PMID: 26860700]

4 **Chalasani N**, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 2012; **55**: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]

5 **Targher G**, Marra F, Marchesini G. Increased risk of cardio­vascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? *Diabetologia* 2008; **51**: 1947-1953 [PMID: 18762907 DOI: 10.1007/s00125-008-1135-4]

6 **Patel YA**, Berg CL, Moylan CA. Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation. *Dig Dis Sci* 2016; **61**: 1406-1416 [PMID: 26815171 DOI: 10.1007/s10620-016-4035-3]

7 **Gitto S**, Vukotic R, Vitale G, Pirillo M, Villa E, Andreone P. Non-alcoholic steatohepatitis and liver transplantation. *Dig Liver Dis* 2016; **48**: 587-591 [PMID: 27038703 DOI: 10.1016/j.dld. 2016.02.014]

8 **Ampuero J**, Romero-Gómez M. [Influence of non-alcoholic fatty liver disease on cardiovascular disease]. *Gastroenterol Hepatol* 2012; **35**: 585-593 [PMID: 22541252 DOI: 10.1016/j.gastrohep. 2012.02.005]

9 **Miura K**, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. *World J Gastroenterol* 2014; **20**: 7381-7391 [PMID: 24966608 DOI: 10.3748/wjg.v20.i23.7381]

10 **Abenavoli L**, Scarpellini E, Rouabhia S, Balsano C, Luzza F. Probiotics in non-alcoholic fatty liver disease: which and when. *Ann Hepatol* 2013; **12**: 357-363 [PMID: 23619251]

11 **Brea A**, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. *Arterioscler Thromb Vasc Biol* 2005; **25**: 1045-1050 [PMID: 15731489 DOI: 10.1161/01.ATV.0000 160613.57985.18]

12 **Kim D**, Choi SY, Park EH, Lee W, Kang JH, Kim W, Kim YJ, Yoon JH, Jeong SH, Lee DH, Lee HS, Larson J, Therneau TM, Kim WR. Nonalcoholic fatty liver disease is associated with coronary artery calcification. *Hepatology* 2012; **56**: 605-613 [PMID: 22271511 DOI: 10.1002/hep.25593]

13 **Puchner SB**, Lu MT, Mayrhofer T, Liu T, Pursnani A, Ghoshhajra BB, Truong QA, Wiviott SD, Fleg JL, Hoffmann U, Ferencik M. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. *Radiology* 2015; **274**: 693-701 [PMID: 25369449 DOI: 10.1148/radiol.14140933]

14 **Ampuero J**, Gallego-Durán R, Romero-Gómez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. *Rev Esp Enferm Dig* 2015; **107**: 10-16 [PMID: 25603326]

15 **Fracanzani AL**, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, Norata D, Valenti L, Grigore L, Porzio M, Catapano A, Fargion S. Progression of carotid vascular damage and cardio­vascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. *Atherosclerosis* 2016; **246**: 208-213 [PMID: 26803429 DOI: 10.1016/j.atherosclerosis.2016.01.016]

16 **Ekstedt M**, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology* 2015; **61**: 1547-1554 [PMID: 25125077 DOI: 10.1002/hep.27368]

17 **European Association for the Study of the Liver (EASL)**, European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016; **64**: 1388-1402 [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004]

18 **Manoushagian S**, Meshkov A. Evaluation of solid organ transplant candidates for coronary artery disease. *Am J Transplant* 2014; **14**: 2228-2234 [PMID: 25220486 DOI: 10.1111/ajt.12915]

19 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines: Liver transplantation. *J Hepatol* 2016; **64**: 433-485 [PMID: 26597456 DOI: 10.1016/j.jhep.2015.10.006]

20 **Wray C**, Scovotti JC, Tobis J, Niemann CU, Planinsic R, Walia A, Findlay J, Wagener G, Cywinski JB, Markovic D, Hughes C, Humar A, Olmos A, Sierra R, Busuttil R, Steadman RH. Liver transplantation outcome in patients with angiographically proven coronary artery disease: a multi-institutional study. *Am J Transplant* 2013; **13**: 184-191 [PMID: 23126562 DOI: 10.1111/j.1600-6143.2012.04293.x]

21 **Williams K**, Lewis JF, Davis G, Geiser EA. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. *Transplantation* 2000; **69**: 2354-2356 [PMID: 10868639]

22 **Snipelisky D**, Levy M, Shapiro B. Utility of dobutamine stress echocardiography as part of the pre-liver transplant evaluation: an evaluation of its efficacy. *Clin Cardiol* 2014; **37**: 468-472 [PMID: 24719365 DOI: 10.1002/clc.22283]

23 **Lentine KL**, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, Carithers RL, Ragosta M, Bolton K, Auerbach AD, Eagle KA. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. *J Am Coll Cardiol* 2012; **60**: 434-480 [PMID: 22763103 DOI: 10.1016/j.jacc.2012.05.008]

24 **Plotkin JS**, Benitez RM, Kuo PC, Njoku MJ, Ridge LA, Lim JW, Howell CD, Laurin JM, Johnson LB. Dobutamine stress echocardiography for preoperative cardiac risk stratification in patients undergoing orthotopic liver transplantation. *Liver Transpl Surg* 1998; **4**: 253-257 [PMID: 9649636]

25 **Di Maira T**, Rubin A, Puchades L, Aguilera V, Vinaixa C, Garcia M, De Maria N, Villa E, Lopez-Andujar R, San Juan F, Montalva E, Perez J, Prieto M, Berenguer M. Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients. *Liver Transpl* 2015; **21**: 812-822 [PMID: 27396823 DOI: 10.1002/lt.24128]

26 **Newsome PN**, Allison ME, Andrews PA, Auzinger G, Day CP, Ferguson JW, Henriksen PA, Hubscher SG, Manley H, McKiernan PJ, Millson C, Mirza D, Neuberger JM, Oben J, Pollard S, Simpson KJ, Thorburn D, Tomlinson JW, Wyatt JS. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. *Gut* 2012; **61**: 484-500 [PMID: 22234978 DOI: 10.1136/gutjnl-2011-300886]

27 **Adam R**, Karam V, Delvart V, O’Grady J, Mirza D, Klempnauer J, Castaing D, Neuhaus P, Jamieson N, Salizzoni M, Pollard S, Lerut J, Paul A, Garcia-Valdecasas JC, Rodríguez FS, Burroughs A. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). *J Hepatol* 2012; **57**: 675-688 [PMID: 22609307 DOI: 10.1016/j.jhep.2012.04.015]

28 **Lucey MR**, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, Teperman LW. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. *Liver Transpl* 2013; **19**: 3-26 [PMID: 23281277 DOI: 10.1002/lt.23566]

29 **Everhart JE**, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. *Liver Transpl Surg* 1998; **4**: 285-296 [PMID: 9649642]

30 **Watt KD**, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. *Am J Transplant* 2010; **10**: 1420-1427 [PMID: 20486907 DOI: 10.1111/j.1600-6143.2010.03126.x]

31 **Madhwal S**, Atreja A, Albeldawi M, Lopez R, Post A, Costa MA. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. *Liver Transpl* 2012; **18**: 1140-1146 [PMID: 22821899 DOI: 10.1002/lt.23508]

32 **VanWagner LB**, Lapin B, Skaro AI, Lloyd-Jones DM, Rinella ME. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. *Liver Int* 2015; **35**: 2575-2583 [PMID: 25977117 DOI: 10.1111/liv.12872]

33 **Gitto S**, Villa E. Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome after Liver Transplant. *Int J Mol Sci* 2016; **17**: 490 [PMID: 27049380 DOI: 10.3390/ijms17040490]

34 **Davis CL**, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. *Liver Transpl* 2002; **8**: 91-109 [PMID: 11862584 DOI: 10.1053/jlts.2002.31516]

35 **Baid S**, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, Tolkoff-Rubin N, Pascual M. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. *Transplantation* 2001; **72**: 1066-1072 [PMID: 11579302]

36 **Rodríguez-Perálvarez M**, Germani G, Papastergiou V, Tsochatzis E, Thalassinos E, Luong TV, Rolando N, Dhillon AP, Patch D, O’Beirne J, Thorburn D, Burroughs AK. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. *J Hepatol* 2013; **58**: 262-270 [PMID: 23023010 DOI: 10.1016/j.jhep.2012.09.019]

37 **Rabkin JM**, Corless CL, Rosen HR, Olyaei AJ. Immuno­suppression impact on long-term cardiovascular complications after liver transplantation. *Am J Surg* 2002; **183**: 595-599 [PMID: 12034401]

38 **Dureja P**, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A. NAFLD recurrence in liver transplant recipients. *Transplantation* 2011; **91**: 684-689 [PMID: 21248661 DOI: 10.1097/TP.0b01 3e31820b6b84]

39 **Yalamanchili K**, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. *Liver Transpl* 2010; **16**: 431-439 [PMID: 20373454 DOI: 10.1002/lt.22004]

40 **VanWagner LB**, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, Lewis CE, Rinella ME, Shah SJ. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. *Hepatology* 2015; **62**: 773-783 [PMID: 25914296 DOI: 10.1002/hep.27869]

41 **Wang X**, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2014; **12**: 394-402.e1 [PMID: 24076414 DOI: 10.1016/j.cgh.2013.09.023]

42 **Malhi H**, Allen AM, Watt KD. Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival. *Curr Opin Organ Transplant* 2016; **21**: 99-106 [PMID: 26825357 DOI: 10.1097/MOT.0000000000000283]

43 **Bellentani S**, Dalle Grave R, Suppini A, Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. *Hepatology* 2008; **47**: 746-754 [PMID: 18098321 DOI: 10.1002/hep.22009]

44 **Khan RS**, Newsome PN. Non-alcoholic fatty liver disease and liver transplantation. *Metabolism* 2016; **65**: 1208-1223 [PMID: 26997540 DOI: 10.1016/j.metabol.2016.02.013]

45 **Albeldawi M**, Aggarwal A, Madhwal S, Cywinski J, Lopez R, Eghtesad B, Zein NN. Cumulative risk of cardiovascular events after orthotopic liver transplantation. *Liver Transpl* 2012; **18**: 370-375 [PMID: 22140067 DOI: 10.1002/lt.22468]

46 **Weick A**, Chacra W, Kuchipudi A, Elbatta M, Divine G, Burmeister C, Moonka D. Incidence of cardiovascular and cerebrovascular events associated with sirolimus use after liver transplantation. *Transplant Proc* 2015; **47**: 460-464 [PMID: 25769591 DOI: 10.1016/j.transproceed.2014.11.036]

47 **Berzigotti A**, Saran U, Dufour JF. Physical activity and liver diseases. *Hepatology* 2016; **63**: 1026-1040 [PMID: 26313307 DOI: 10.1002/hep.28132]

48 **Dam-Larsen S**, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, Becker U, Bendtsen F. Long term prognosis of fatty liver: risk of chronic liver disease and death. *Gut* 2004; **53**: 750-755 [PMID: 15082596]

49 **Adams LA**, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology* 2005; **129**: 113-121 [PMID: 16012941]

50 **Ong JP**, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. *J Hepatol* 2008; **49**: 608-612 [PMID: 18682312 DOI: 10.1016/j.jhep.2008.06.018]

51 **Rafiq N**, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. *Clin Gastroenterol Hepatol* 2009; **7**: 234-238 [PMID: 19049831 DOI: 10.1016/j.cgh.2008.11.005]

52 **Söderberg C**, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. *Hepatology* 2010; **51**: 595-602 [PMID: 20014114 DOI: 10.1002/hep.23314]

53 **Angulo P**, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2015; **149**: 389-397.e10 [PMID: 25935633 DOI: 10.1053/j.gastro.2015.04.043]

54 **Stepanova M**, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, McCullough A, Goodman Z, Younossi ZM. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). *Dig Dis Sci* 2013; **58**: 3017-3023 [PMID: 23775317 DOI: 10.1007/s10620-013-2743-5]

Footnotes

Conflict-of-interest statement:None.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Peer-review started:February 9, 2017

First decision:March 6, 2017

Article in press: April 24, 2017

**P- Reviewer**: Abenavoli L, Akamatsu N, Chiu KW, Gonzalez-Reimers E **S- Editor**:Ji FF **L- Editor**: A **E- Editor**:Li D

**Table 1 Methods to detect subclinical atherosclerosis[8]**

|  |  |  |
| --- | --- | --- |
| Carotid ultrasound | CIMT | > 0.9 mm |
| CT coronary angiography | No. of calcifications in coronary arteries | ≥ 1 |
| Endothelial function | Flow-mediated vasodilation brachial artery |  |
|  | Carotid-femoral pulse wave velocity  | > 12 m/s |
| Morpho-structural alteration | Electrocardiogram (left ventricular hypertrophy) | Sokolov-Lyon > 38 mm; cornell > 2444 mm\*ms |
| Renal function | Slight increase in plasmatic creatinine | M: 1.3-1.5 mg/dL |
|  |  | F: 1.2-1.4 mg/dL |
|  | Low glomerular filtration | Creatinine clearance < 60 mL/min |
|  | Microalbuminuria  | 30-300 mg/24 h |
|  |  | Alb/Cr ≥ 22 (M) or ≥ 31 (F) mg/g Cr |
| Inflammatory biomarkers | TNF, IL-6, C-reactive protein |  |
| Thrombogenic biomarkers  | PAI-1, fibrinogen, factor VII |  |

CIMT: Carotid intima-media thickness; CT: Computerized tomography; M: Male; F: Female; TNF: Tumor necrosis factor; IL: Interleukin; PAI-1: Plasminogen activator inhibitor type 1.

**Table 2 Cardiovascular mortality in non-alcoholic fatty liver disease patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **NAFLD diagnosis** | **Follow-up** | **CV mortality** | **Cause of mortality** |
| Dam-Larsen *et al*[48]  | 2004 | Histology | 20 yr | 38% | 1st |
| Adams *et al*[49] | 2005 | Histology |  8 yr | 25% |  2nd |
| Ong *et al*[50] | 2008 | Ultrasound |  9 yr | 25% | 1st |
| Rafiq *et al*[51] | 2009 | Histology | 29 yr | 13% | 1st |
| Söderberg *et al*[52]  | 2010 | Histology | 28 yr | 35% | 1st |
| Angulo *et al*[53]  | 2013 | Histology |  9 yr | 38% | 1st |
| Stepanova *et al*[54]  | 2013 | Histology | 12 yr | 28% | 1st |
| Ekstedt *et al*[16]  | 2015 | Histology | 26 yr | 43% | 1st |

CV: Cardiovascular; NAFLD: Non-alcoholic fatty liver disease.

**Table 3 Immunosuppressive drugs and metabolic side effects affecting post-liver transplantation cardiovascular risk[33]**

|  |  |  |
| --- | --- | --- |
| **Drug** | **Group** | **Side effects** |
| Corticosteroids |  | Dyslipidemia ++ |
|  |  | AHT +++ |
|  |  | DM +++ |
|  |  | Renal impairment - |
| Mycophenolate mofetil | *De novo* purine synthesis inhibitor | Dyslipidemia - |
|  | AHT - |
|  | DM - |
|  | Renal impairment - |
| Cyclosporine | Calcineurin inhibitors | Dyslipidemia ++ |
| Tacrolimus | AHT +++ |
|  | DM ++ |
|  | Renal impairment ++ |
| Sirolimus | mTOR inhibitors | Dyslipidemia +++ |
| Everolimus | AHT - |
|  | DM - |
|  | Renal impairment - |

(+): Positive association; (-): No association; AHT: Arterial Hypertension; DM: Diabetes mellitus.